Zbiciak-Nylec Martyna, Wcisło-Dziadecka Dominika, Brzeziñska-Wcisło Ligia
Andrzej Mielêcki Silesian Independent Public Clinical Hospital, Katowice, Poland.
Chair of Cosmetology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec (SPLMS in Sosnowiec), Medical University of Silesia, Katowice, Poland.
Postepy Dermatol Alergol. 2020 Aug;37(4):524-530. doi: 10.5114/ada.2020.98239. Epub 2020 Sep 2.
The aim of the study was to assess of sTNFαR1 concentration in the serum of patients with localized scleroderma (in comparison with a control group).
This was a prospective study. The patients with localized scleroderma were divided into two groups: 21 persons treated with PUVA therapy and 20 persons treated with procaine penicillin. In the case of the patients treated with intramuscularly administered procaine penicillin (dose: 2,400,000 IU/day), achievement of a total dose of at least 30 million IU/day was considered as the end of the therapy. In the group of patients treated with photochemotherapy, the single initial dose during a PUVA session was 0.5 J/cm and it was increased by 0.5 J/cm every other day to reach the maximum value of 10 J/cm, depending on the clinical condition. The study involved three sessions a week.
sTNFαR1 concentration in the serum of patients with localized scleroderma was significantly higher in comparison with the control group and correlated with the skin damage index. The difference in the determined particle level was higher in the group of patients undergoing photochemotherapy (median: 106.25 ng/ml) than in the group taking penicillin (median: 81.50 ng/ml). Patients treated with PUVA sessions demonstrated a greater decrease in sTNFαR1 concentration and an improvement of the clinical condition after therapy completion.
The obtained results suggest a potential role of sTNFαR1 in the pathogenesis of localized scleroderma.
本研究旨在评估局限性硬皮病患者血清中可溶性肿瘤坏死因子α受体1（sTNFαR1）的浓度（与对照组进行比较）。
这是一项前瞻性研究。局限性硬皮病患者被分为两组：21例接受补骨脂素紫外线A光化学疗法（PUVA）治疗，20例接受普鲁卡因青霉素治疗。对于肌肉注射普鲁卡因青霉素治疗的患者（剂量：240万国际单位/天），总剂量达到至少3000万国际单位/天被视为治疗结束。在光化学疗法治疗的患者组中，PUVA治疗期间的单次初始剂量为0.5焦/平方厘米，根据临床情况每隔一天增加0.5焦/平方厘米，直至达到最大值10焦/平方厘米。该研究每周进行三次治疗。
与对照组相比，局限性硬皮病患者血清中的sTNFαR1浓度显著更高，且与皮肤损伤指数相关。接受光化学疗法的患者组中所测定的颗粒水平差异（中位数：106.25纳克/毫升）高于服用青霉素的患者组（中位数：81.50纳克/毫升）。接受PUVA治疗的患者在治疗结束后sTNFαR1浓度下降幅度更大，临床状况得到改善。
所得结果表明sTNFαR1在局限性硬皮病的发病机制中可能发挥作用。
